Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

An announcement made by the Swiss drugmaker Novartis AG (NVS: Quote) on Wednesday suggested about the late-breaking results omalizumab clearing all the primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria or CSU.

It is a chronic and debilitating form of hives with partial approved treatment options. GLACIAL is considered as the second of three pivotal Phase III studies. These studies conduct analysis about the efficacy and safety of omalizumab in CSU.

The result derived from the study supported supported the efficacy, safety and tolerability of omalizumab in patients with refractory CSU. It is a kind of chronic and debilitating skin disease with obstinate itch and hives.

Near about 40 percent of CSU patients were unsuccessful on ntihistamines. These include those who were taking the approved dose even for the fourth time. The doses, in terms of official regulations are currently available only for treatment for CSU.

However, Omalizumab is presently not at all approved or indicated for CSU. Supervision of the submissions for omalizumab in CSU is scheduled for later times in the current year. It is a collaborated effort of Novartis and Genentech, Inc.

The data was brought forward for the first time at the European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress 2013 in Milan which is located in Italy.


FrenchTribune Specials

Extremely Small Premature Baby Surprises Everyone

Megan Smith and Eric Pegues finally took a sigh of relief after their extremely small premature baby was discharged on January 9, 2016 from a hospital in Charlotte, North Carolina. Megan, who gave birth to E’layah Faith on September 23, 2015, said that she was anxious as the moment she had been waiting for has finally arrived.

The baby...

Most Popular

CNIL asks Facebook to comply with French data protection laws or face fines

This week, social network Facebook has been ordered by...

Junior doctors in England begin second 24-hour strike

Junior doctors in England are starting another day long...

Hackers expose contact details of 20,000 FBI employees

The contact information of 20,000 employees from the...

Indian regulators block Facebook's ‘Free Basics’ service

On Monday, the Telecom Regulatory Authority of India (...

Poll

Can Greece Come out of Economic Problems: